Effects of sigma receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat

European Journal of Pharmacology
G A Gudelsky

Abstract

The extracellular concentration of dopamine in the striatum and medial prefrontal cortex of the rat was determined following the systemic administration of sigma receptor ligands. The (+)-benzomorphan, (+)-pentazocine, significantly increased the extracellular concentration of dopamine in the striatum also was produced by the (+)-, but not the (-)-, enantiomer of N-allylnormetazocine, as well as by the non-benzomorphans 1-(cyclopropylmethyl)-4-(2'-(4"-fluorophenyl)-2'-oxoothyl-piper idi ne (DUP 734) and (-)-butaclamol. In contrast, the dopamine concentration was unaffected by di-o-tolylguanidine and markedly suppressed by (+)-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine (3-PPP). Finally, the (+)-pentazocine-induced elevation of the extracellular concentration of dopamine was not suppressed by an inhibitor of the dopamine transporter, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-[3-phenylpropyl]piperazine (GBR 12909). Thus, benzomorphan, e.g., (+)-pentazocine and (+)-N-allylnormetazocine, and non-benzomorphan, e.g., DUP 734 and (-)-butaclamol, sigma receptor ligands appear to facilitate dopamine release from nigrostriatal, and presumably mesocorticolimbic, neurons through a non-transporter-mediated mechanism.

References

Mar 1, 1992·Trends in Pharmacological Sciences·R QuirionD P Taylor
Feb 1, 1992·Neuropharmacology·G A Gudelsky, J F Nash
Feb 1, 1988·Journal of Neurochemistry·S P ButcherG W Arbuthnott
Jul 18, 1989·European Journal of Pharmacology·Y L Hurd, U Ungerstedt
Jan 1, 1988·Synapse·P C ContrerasC C Lair
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Sep 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S W Tam, L Cook
Mar 1, 1995·Naunyn-Schmiedeberg's Archives of Pharmacology·R BergeronG Debonnel
Oct 15, 1993·Journal of Medicinal Chemistry·C SonessonH Wikström
Jan 1, 1993·Annual Review of Pharmacology and Toxicology·L S SeidenG A Ricaurte

❮ Previous
Next ❯

Citations

Apr 15, 2003·Annals of Nuclear Medicine·Kiichi IshiwataKiyoshi Matsuno
Oct 27, 1998·European Journal of Pharmacology·S D GlickI M Maisonneuve
Oct 24, 2003·Neuropharmacology·Delphine MoisonUmberto Spampinato
Sep 3, 2002·Neuroscience and Biobehavioral Reviews·Tangui MauriceRae R Matsumoto
May 23, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Rotem GenudGal Yadid
Nov 29, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Takato HiranitaJonathan L Katz
Apr 20, 2004·The European Journal of Neuroscience·Magali PeetersEmmanuel Hermans
May 5, 2010·Pharmacology & Therapeutics·James A FishbackRae R Matsumoto
Sep 10, 2011·Pharmaceuticals·Jonathan L KatzShang-Yi Tsai
Jan 29, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Yakup AlbayrakEce Altındağ
Feb 24, 2004·CNS Drug Reviews·Deborah L GilmoreRae R Matsumoto
Dec 8, 2015·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Nisha K RamakrishnanAren van Waarde
Feb 25, 2021·Journal of Neural Transmission·Wojciech DanyszPeter Riederer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.